Adjusted earnings per share was $3.19 representing year-over-year growth of 25.1% on a reported and 22.7% on a currency-neutral basis.
Our adjusted earnings per share increased 25.1% over the prior year to $3.19 on a reported basis and were up 22.7% on an FX-neutral basis.
Adjusted earnings per share was $3.19 representing year-over-year growth of 25.1% on a reported and 22.7% on a currency-neutral basis.
Our adjusted earnings per share increased 25.1% over the prior year to $3.19 on a reported basis and were up 22.7% on an FX-neutral basis.
Our second quarter revenues totaled $4.9 billion, up 15.4% on a reported basis and up 12.2% on an FX-neutral basis.
Our revenues came in just over $4.9 billion, up 15.4% on a reported basis and up 12.2% on an FX-neutral basis.
Our COVID-19 diagnostic testing revenues totaled $480 million and are included in our Integrated Diagnostics Solutions business.
